Europe Isotretinoin Drugs Market, By Indication

Growth Outlook

• The Europe Isotretinoin Drugs Market, By Indication market is on a steady long-term growth path. Segment value stands at roughly USD 405 Mn in 2026 and is projected to reach USD 424 Mn by 2027 — a gain of about 5% over the forecast period, translating to a CAGR in the mid-single digits.
• Severe Acne is the biggest of 9 groups as of 2027, at 95. 66M USD (23% of the combined total).
• What the regional split looks like (2026): Severe Acne leads, holding roughly 22% of segment value — the single largest regional share. Alpha Glucosidase Inhibitors is the second-largest contributor. Squamous Cell Carcinoma, Cutaneous T-Cell Lymphoma, Neuroblastoma, Others, Harlequin Ichthyosis, Xeroderma Pigmentosum and Fibrodysplasia Ossificans Progressiva make up the remainder, in descending order.
• By 2027, Severe Acne alone is expected to reach USD 96 Mn, with Alpha Glucosidase Inhibitors at USD 85 Mn.

Market Dynamics

Severe Acne is the biggest of 9 groups as of 2027, at 95.66M USD (23% of the combined total).

Alpha Glucosidase Inhibitors is runner-up at 84.75M USD — 11% off the lead.

Severe Acne: 61.19M USD in 2018 to 95.66M USD by 2027, up 56%.

Alpha Glucosidase Inhibitors grows to 84.75M USD by 2027, from 59.30M USD in 2018 — 43% up.

Squamous Cell Carcinoma climbs from 49.69M USD (2018) to 66.45M USD (2027), a 34% gain.

Cutaneous T-Cell Lymphoma: 45.36M USD to 57.29M USD, 26% higher by 2027.

Neuroblastoma: up 17% over the period, 26.90M USD to 31.60M USD.

Others grows to 29.68M USD by 2027, from 25.71M USD in 2018 — 15% up.

The 9-group total: 322.99M USD in 2018, 424.35M USD by 2027, 31% overall.

Making Sense Of 9 Series At Once

With 9 series on one chart, the shape that matters is how the ranking shifts over time, not just where each line starts or ends.

Do not confuse "biggest" with "fastest-growing" — they are frequently different series on a chart like this one, and the gap between them can close faster than the current ranking suggests.

Use this chart to size the Europe Isotretinoin Drugs market and to compare how fast it is expected to grow against adjacent markets — it works best as an input to a market-entry or investment decision, not as a standalone verdict.

Figures before the 2018 base year are historical estimates; the years through 2027 are projections built from industry data, company revenues, and primary interviews. Forecasts are revised as new data comes in, so check the full report for the latest assumptions.